Featured Research

from universities, journals, and other organizations

Mice with human body's defenses

Date:
October 5, 2010
Source:
Helmholtz Association of German Research Centres
Summary:
Therapeutic antibodies can be an efficient alternative when common drugs do not work anymore. However, antibodies obtained from blood of animals such as mice could not be used: The human immune system recognizes them as foreign and rejects them. Scientists have now succeeded in developing a promising approach to solve this problem.

Therapeutic antibodies can be an efficient alternative when common drugs do not work anymore. However, antibodies obtained from blood of animals such as mice could not be used: The human immune system recognizes them as foreign and rejects them. In an international cooperation, scientists from the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany have now succeeded in developing a promising approach to solve this problem; with the help of human stem cells they generated mice with a human immune system, which were then vaccinated to produce human monoclonal antibodies.

These fully human antibodies could help in the research and therapy of human diseases. Their results have now been published in the current online issue of the scientific journal PLoS One.

Antibodies are small proteins, produced by B cells during an immune response. They bind at and thus mark invading pathogens so that scavenger cells recognize and destroy them. "The task of our immune system is to distinguish between self and non-self structures," says Professor Carlos A. Guzmàn, head of the department of "Vaccinology and Applied Microbiology" at the HZI. "This means also that only human antibodies come into question for an antibody therapy," since the human immune system fights antibodies from mice -- a threat for the patient. Furthermore, it is cumbersome to humanize murine antibodies for human treatment or to generate human B cell clones producing high quantities of antibodies.

The scientists used an already established method to give a human immune system to mice, which were then exploited to solve this problem: they injected human stem cells into young mice that due to a genetic defect lack an immune system. The stem cells migrate into the bone marrow, proliferate, differentiate and lead to the generation of a human immune system. "In our in-depth investigations we were able to detect all important types of immune cells in these mice," says Dr. Pablo Becker, scientist in the HZI department "Vaccinology and Applied Microbiology."

To validate the new approach, mice with a human immune system were vaccinated against Hepatitis B or Tetanus. The scientists then isolated human antibody producing B cells from the mice and treated them so that they survive outside the body in a cell culture dish and continue producing antibodies. Then, the researchers took a deeper look at the antibodies. The results give hope: "Antibodies from mice with a human immune system showed good properties in our tests, but the model still needs to be improved for broad implementation in biomedicine," says Pablo Becker. "However, we were able to demonstrate for the first time that it is possible to produce human monoclonal antibodies using humanized mice." Now it is important to improve this mouse model to use it one day for the development of advanced therapies against human diseases. "In the future this approach might represent the most powerful tool to develop therapeutic antibodies for clinical use," hopes Becker.


Story Source:

The above story is based on materials provided by Helmholtz Association of German Research Centres. Note: Materials may be edited for content and length.


Journal Reference:

  1. Derya Unutmaz, Pablo D. Becker, Nicolas Legrand, Caroline M. M. van Geelen, Miriam Noerder, Nicholas D. Huntington, Annick Lim, Etsuko Yasuda, Sean A. Diehl, Ferenc A. Scheeren, Michael Ott, Kees Weijer, Heiner Wedemeyer, James P. Di Santo, Tim Beaumont, Carlos A. Guzman, Hergen Spits. Generation of Human Antigen-Specific Monoclonal IgM Antibodies Using Vaccinated "Human Immune System" Mice. PLoS ONE, 2010; 5 (10): e13137 DOI: 10.1371/journal.pone.0013137

Cite This Page:

Helmholtz Association of German Research Centres. "Mice with human body's defenses." ScienceDaily. ScienceDaily, 5 October 2010. <www.sciencedaily.com/releases/2010/10/101005104444.htm>.
Helmholtz Association of German Research Centres. (2010, October 5). Mice with human body's defenses. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/10/101005104444.htm
Helmholtz Association of German Research Centres. "Mice with human body's defenses." ScienceDaily. www.sciencedaily.com/releases/2010/10/101005104444.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins